Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in an all-stock merger that will create a central nervous system (CNS)-focused biopharmaceutical company with 11 marketed products. The merged business is expected to generate approximately $2.2 billion in annual revenue and about $888 million in operating earnings.
The combined company will continue operating under the Supernus name and remain listed on Nasdaq under the ticker symbol “SUPN.” Current Supernus Chief Executive Officer Jack Khattar will lead the merged organization, while Indivior board member Tony Kingsley will serve as chair of the board.
Merger Brings Together CNS Product Portfolios
The companies said the merger is expected to produce approximately $125 million in annual cost savings. While specific efficiency measures were not outlined, Khattar indicated that the savings would involve “natural redundancies,” particularly within general and administrative functions.
The companies expect the combined business to have net debt of approximately $878 million.
Management said the transaction is intended to increase financial flexibility and support internal and external growth opportunities, including additional acquisitions. During an investor call, Khattar said the company would also consider business development opportunities in women’s health, an area where Supernus already has an established presence.
Financial Structure and Expected Savings
The companies said the merger is expected to produce approximately $125 million in annual cost savings. While specific efficiency measures were not outlined, Khattar indicated that the savings would involve “natural redundancies,” particularly within general and administrative functions.
The companies expect the combined business to have net debt of approximately $878 million.
Management said the transaction is intended to increase financial flexibility and support internal and external growth opportunities, including additional acquisitions. During an investor call, Khattar said the company would also consider business development opportunities in women’s health, an area where Supernus already has an established presence.
Leadership and Ownership Details
“We view this as being the ideal time for two companies that have done so much, progressed so much, that are in a position of strength, getting together and creating a very powerful combination that otherwise would not exist,” Khattar said during a conference call.
Under the terms of the agreement, Supernus shareholders will receive 1.5401 shares of Indivior common stock for each Supernus share they own. Indivior shareholders will receive a special cash dividend totaling $1 billion upon completion of the merger.
To fund the dividend, the companies secured a $650 million loan from Citibank. Once the transaction closes, former Indivior shareholders are expected to own 56.5% of the combined company, while former Supernus shareholders will own 43.5%.
The new board of directors will include four members from each company. Both boards have approved the transaction, which is expected to close during the fourth quarter of the year.
Supernus and Indivior Announce All-Stock Merger
Supernus and Indivior have agreed to combine their businesses through an all-stock merger, creating a new company focused on central nervous system (CNS) therapies. The transaction positions Supernus to become part of a broader neuroscience-focused organization.
The proposed combination brings together complementary pharmaceutical portfolios and commercial capabilities. For Supernus, the merger could provide greater scale and resources to pursue opportunities across CNS disorders.
The proposed all-stock merger represents a significant development in the CNS pharmaceutical sector. By bringing two established businesses together, the new organization could gain greater scale, a broader product portfolio, and expanded commercial capabilities.
The transaction is also expected to create opportunities to streamline operations and combine specialized expertise. A larger platform may provide additional resources for research, development, and commercialization of treatments for neurological and psychiatric conditions.
Expanding the CNS Portfolio
The combined company is expected to maintain a strong focus on central nervous system disorders. This strategy could allow the organization to concentrate resources on areas where patients continue to face significant treatment challenges.
A broader portfolio can also help diversify revenue streams and reduce reliance on individual products. At the same time, integrating different development programs and commercial teams will require careful planning.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
